News | Prostate Cancer | July 13, 2016

Washington Hospital Using MRI-Guided Technology to Reduce Unnecessary Prostate Cancer Surgeries

Overlake Medical Center first in region to adopt new standard of care

prostate cancer, MRI-guided biopsies, Overlake Medical Center Washington

July 13, 2016 — Overlake Medical Center, Bellevue, Wash., recently announced it is formally adopting a new standard of care for prostate cancer treatment with the potential to dramatically decrease instances of over-treatment. The improvements are a result of magnetic resonance imaging (MRI) technologies to diagnose and guide biopsies to more accurately identify the cancer type and inform treatment.

Prostate cancer is the most common form of cancer for men and the second-leading cause of death. However, not all prostate cancers are created equal, with some less aggressive than others. Treating all cancers the same has led to over-treatment that can have lasting quality-of-life issues, such as incontinence and erectile dysfunction.

“One in seven men will be diagnosed with prostate cancer during his lifetime, but not all prostate cancers require immediate treatment,” said urologic oncologist Khanh Pham, M.D., with Washington Urology Associates. “In the past it has been a challenge to distinguish between tumors that are potentially deadly and those that are indolent.

“We are pleased that Overlake is at the forefront of care, investing in technology that helps us better view high-grade tumors, as well as perform MRI-guided prostate biopsies, which both have huge positive ramifications for patient care.”

David Winokur, Overlake’s medical imaging director, explained, “Typically, a patient may come in with elevated prostate-specific antigens (PSA) in their blood, but that number can be the result of anything from aggressive cancer to a simple infection, so an accurate diagnosis is crucial.

“MRI technology gives us the ability to view detailed cross-sectional images of the prostate and provide a much more accurate view of the type of tumor we’re dealing with.

“In addition, MRI-guided biopsies are a game changer. We now have the ability to pinpoint exactly where the tumor is and biopsy the precise target rather than the traditional ‘shotgun approach’ of ultrasound-guided biopsies,” Winokur said.

In the past, since diagnostic information has been limited and inexact, most patients and doctors understandably err on the side of more aggressive treatment.

“Patients need to fully educate themselves on their diagnosis and treatment options,” said Pham. “Guidelines from the American Cancer Society as well as the American Urological Association have evolved to include active surveillance as an acceptable and viable management option for men with low-grade, indolent prostate cancer. Aggressive treatment, with either surgery or radiation therapy, still remains important in the management of prostate cancer for appropriately selected patients, but may not the best solution in many cases, and Overlake’s new standard of care reflects that.”

For more information: www.overlakehospital.org

Related Content

Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
Ingenia Ambition X 1.5T MR. This innovation is the latest advance in the Ingenia MRI portfolio, which comprises fully-digital MRI systems, healthcare informatics and a range of maintenance and life cycle services for integrated solutions that empower a faster, smarter, and simpler path to enabling a confident diagnosis
News | Magnetic Resonance Imaging (MRI) | September 14, 2018
Philips, a global leader in health technology, launched the Ingenia Ambition X 1.5T MR.
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Veye Chest version 2
News | Lung Cancer | September 11, 2018
Aidence, an Amsterdam-based medical AI company, announced that Veye Chest version 2, a class IIa medical device, has
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...
Sponsored Content | Case Study | Magnetic Resonance Imaging (MRI) | September 07, 2018 | By Sabine Sartoretti, M.D.
As soon as the Compressed SENSE technology became available to the MRI team at Kantonsspital Winterthur (Switzerland),...

Image courtesy of IBA

Feature | Radiation Oncology | September 07, 2018 | By Jeff Zagoudis
According to the latest statistics from the American Cancer Society (ACS), almost 165,000 new cases of prostate cancer...

Image courtesy of Philips Healthcare

Feature | Magnetic Resonance Imaging (MRI) | September 06, 2018 | By Melinda Taschetta-Millane
According to the Prescient & Strategic Intelligence report, “Global Magnetic Resonance Imaging (MRI) Market Size,...